![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Methyl-CpG binding domain protein 1 (MBD1) is a transcriptional regulator that
binds methylated CpG islands of tumor suppressor genes and represses their
transcription. In a former study, we found high expression of MBD1 in pancreatic
cancer cell lines and tissues which may play an important role in the development of
pancreatic cancer. In the present study, we incorporated the siRNA sequence of
MBD1 plasmid into a PLGA:Poloxamer carrier to test the therapeutic effect of this
compound on BxPC-3 human pancreatic cancer cells. We found that an MBD1 siRNA
plasmid can be successfully transfected into tumor cells and the MBD1 nanoparticle
compound can inhibit cell growth and induce apoptosis. The MBD1 nanoparticle is a
promising candidate for gene therapy of pancreatic cancer in vitro.